News Search

Showing 41 - 50 of 166 results.

Bivalent COVID Boosters Offer No Extra Protection, Studies Suggest

Source:

U.S.News

January 11, 2023

The updated COVID-19 vaccine boosters don’t appear to provide any better protection than the original shot does.
Biden administration extends Covid public health emergency as highly infectious omicron XBB.1.5 spreads

Source:

CNBC

January 11, 2023

the U.S. may face another wave of hospitalizations from the disease this winter.
Omicron offshoot XBB.1.5 could drive new Covid-19 surge in US

Source:

CNNhealth

January 3, 2023

Omicron descendants, BQs – BQ.1, BQ.1.1, and XBB.1.5, are spreading fast in the US.
Omicron BQ, XBB subvariants are a serious threat to boosters and knock out antibody treatments, study finds

Source:

CNBC

December 14, 2022

The BQ.1, BQ.1.1, XBB and XBB.1 omicron subvariants are the most immune evasive variants of Covid-19 to date.
What you need to know about covid boosters and the latest research

Source:

The Washington Post

November 2, 2022

New studies are fueling debate about whether the booster shot targeting the BA.4 and BA.5 versions of omicron is superior to another shot of the original.
Two new research papers cast doubt on the new COVID booster

Source:

npr

October 25, 2022

Researchers at Columbia and Harvard compared how the immune systems of volunteers responded to the new bivalent boosters versus the original vaccine.
New Covid Boosters Aren’t Better Than Old Ones, Study Finds

Source:

Bloomberg

October 25, 2022

Results show the new shots perform similarly to past ones. Moderna, Pfizer boosters aim to protect against new variants
Which COVID studies pose a biohazard? Lack of clarity hampers research

Source:

nature

October 21, 2022

Controversy surrounding a study that involved modifying the SARS-CoV-2 virus has prompted researchers to call for better guidance from funders.
Longer Paxlovid course doesn't reduce risk of rebound, study finds

Source:

Becker's Healthcare

October 7, 2022

Is five days of treatment of Paxlovid enough?
Amid COVID's latest surge, Regeneron and Eli Lilly score new antibody supply deals with the U.S.

Source:

Fierce Pharma

September 15, 2022

Regeneron will supply an additional 1.4 million antibody doses to the United States, while Eli Lilly will provide 388,000 additional doses of its antibodies.

News Search

Source:

Source:

Source:

Source:

Source:

Source:

Source:

Source:

Source:

Source:

Pages